 Oramed Pharmaceuticals NASDAQ:ORMPs stock had its buy rating reiterated by analysts at HC Wainwright in a research report issued on Monday, The Fly reports. They presently have a 17.00 price objective on the biotechnology companys stock, up from their previous price objective of 16.00. HC Wainwrights price objective indicates a potential upside of 410.51 from ... 